These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24142206)

  • 1. Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarin.
    Stoch SA; Witter R; Hrenuik D; Liu C; Zajic S; Mehta A; Chandler P; Morris D; Xue H; Denker A; Wagner JA
    J Popul Ther Clin Pharmacol; 2013; 20(3):e312-20. PubMed ID: 24142206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Krishna R; Stypinski D; Ali M; Garg A; Cote J; Maes A; Degroot B; Liu Y; Li S; Connolly SM; Wagner JA; Stoch SA
    Br J Clin Pharmacol; 2012 Jul; 74(1):116-24. PubMed ID: 22243494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
    Wright DH; Herman GA; Maes A; Liu Q; Johnson-Levonas AO; Wagner JA
    J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women.
    Anderson MS; Gendrano IN; Liu C; Jeffers S; Mahon C; Mehta A; Mostoller K; Zajic S; Morris D; Lee J; Stoch SA
    J Clin Endocrinol Metab; 2014 Feb; 99(2):552-60. PubMed ID: 24276460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    He YL; Sabo R; Riviere GJ; Sunkara G; Leon S; Ligueros-Saylan M; Rosenberg M; Dole WP; Howard D
    Curr Med Res Opin; 2007 May; 23(5):1131-8. PubMed ID: 17519080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Graefe-Mody EU; Brand T; Ring A; Withopf B; Stangier J; Iovino M; Woerle HJ
    Int J Clin Pharmacol Ther; 2011 May; 49(5):300-10. PubMed ID: 21543033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
    Gu N; Kim BH; Lim KS; Kim SE; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI; Liu F; Stroh M; Gipson A; Johnson-Levonas AO; Lasseter KC; Lai E; Wagner JA
    Am J Ther; 2009; 16(3):215-23. PubMed ID: 19454860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers.
    Macha S; Rose P; Mattheus M; Pinnetti S; Woerle HJ
    Diabetes Obes Metab; 2013 Apr; 15(4):316-23. PubMed ID: 23094794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of clinically relevant drug-drug interaction between odanacatib and digoxin after concomitant administration.
    Stoch SA; Witter R; Hreniuk D; Liu C; Zajic S; Mehta A; Brandquist C; Dempsey C; Degroot B; Stypinski D; Denker A; Wagner JA
    Int J Clin Pharmacol Ther; 2013 Aug; 51(8):688-92. PubMed ID: 23782582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.
    Walker G; Mandagere A; Dufton C; Venitz J
    Br J Clin Pharmacol; 2009 May; 67(5):527-34. PubMed ID: 19552747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Malhotra B; Alvey C; Gong J; Li X; Duczynski G; Gandelman K
    Br J Clin Pharmacol; 2011 Aug; 72(2):257-62. PubMed ID: 21496065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs - midazolam and odanacatib.
    Marcantonio EE; Ballard J; Gibson CR; Kassahun K; Palamanda J; Tang C; Evers R; Liu C; Zajic S; Mahon C; Mostoller K; Hreniuk D; Mehta A; Morris D; Wagner JA; Stoch SA
    J Clin Pharmacol; 2014 Nov; 54(11):1280-9. PubMed ID: 24895078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
    Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin.
    Ouellet D; Bramson C; Carvajal-Gonzalez S; Roman D; Randinitis E; Remmers A; Gardner MJ
    Br J Clin Pharmacol; 2006 Jun; 61(6):741-5. PubMed ID: 16722839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy Subjects.
    Stoch SA; Ballard J; Gibson C; Kesisoglou F; Witter R; Kassahun K; Zajic S; Mehta A; Brandquist C; Dempsey C; Stypinski D; Reitman ML
    J Clin Pharmacol; 2017 Jan; 57(1):110-117. PubMed ID: 27321774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetic Analysis of the Cathepsin K Inhibitor Odanacatib: Insights Into Intrinsic and Extrinsic Factor Effects on Exposure in Postmenopausal and Elderly Women.
    Jaworowicz D; Bihorel S; Zajic S; Stoch SA; Humphrey R; McCrea JB; Stone JA
    J Clin Pharmacol; 2020 Aug; 60(8):1107-1123. PubMed ID: 32302427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin.
    Stockis A; van Lier JJ; Cawello W; Kumke T; Eckhardt K
    Epilepsia; 2013 Jul; 54(7):1161-6. PubMed ID: 23614393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
    Stone JA; McCrea JB; Witter R; Zajic S; Stoch SA
    Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.